There’s a difference between a cheap stock and a bargain. A cheap stock might be cheap because it’s broken. A bargain is a quality company that’s been temporarily beaten down by concerns that the market has overpriced.
Three dividend-paying stocks stand out as bargains right now. All three are trading at significant discounts from recent highs. All three have been punished by specific concerns that deserve scrutiny. But all three have the potential to recover once those concerns recede and the market reassesses valuations.
Novo Nordisk: Competitive Pressure on a Powerful Brand
Novo Nordisk shares are down more than 60% from their mid-2024 peak. The cause is clear: the GLP-1 weight-loss drug race that Novo helped start has become intensely competitive. Rival Eli Lilly is taking market share. Novo is facing price pressure. The company’s decision to file a lawsuit against Lilly over advertising claims suggests some desperation.
This is a real problem that deserves attention. The competitive dynamics are unfavorable. The company is in a “reset” year sooner than investors expected.
But here’s what’s important: all of these concerns have already been reflected in the stock price. The company is now trading at less than 12 times trailing earnings. The dividend yield is 3.74% on a forward-looking basis.
What investors might be overlooking is that Wegovy is still a powerful brand with significant market potential. The company has 32 drug trials underway, nine of which are in phase 3. The cash flow supporting dividend payments will remain intact while the company works through this reset.
Novo Nordisk isn’t the most attractive story right now. But at current prices, the downside is limited and the dividend provides income while you wait for the competitive situation to stabilize. The market has overshot in pricing in all the bad news.
PepsiCo: Temporary Margin Pressure on a Blue Chip
PepsiCo shares are down 20% from their early February peak, which has pushed the forward P/E down to a multiyear low of less than 16 and the dividend yield up to 4.4%.
The weakness makes sense superficially. Organic revenue growth is tepid at 2.5%, weighed down by its North American food business. Cost and health concerns are contributing factors. Last quarter’s core operating margin of 16.8% was down 40 basis points from the year-ago comparison.
But there’s nothing PepsiCo is going through now that it hasn’t been through and survived before. These are slow-moving economic issues, not business model problems. The company isn’t being disrupted. It’s not losing competitive position. It’s facing the same headwinds it’s navigated for decades.
What makes this interesting is that PepsiCo has now raised its dividend for 54 consecutive years. That streak didn’t happen by accident. It happened because the company has deep moats and resilient cash flows.
At 20% below its February high and more than 30% below its 2023 peak, PepsiCo is offering a quality blue chip at a discount. The dividend yield of 4.4% provides income while you wait for the near-term headwinds to ease. That’s the definition of a bargain.
Accenture: AI Fears Overblown on a Quality Services Business
Accenture has suffered a 64% setback since February last year. The reason is obvious: investors fear that artificial intelligence will eventually replicate much of what the company does—strategy consulting, technology implementation, cybersecurity, supply chain optimization, and more.
That fear deserves to be taken seriously. AI is advancing quickly. It will displace some consulting work. That’s real.
But what’s become clear over the past year is that AI can’t do everything, and much of what it can do, it doesn’t do particularly well. Companies still need experienced people to make judgment calls and apply common sense that AI platforms often lack. That’s actually good news for Accenture and its shareholders. The existential threat that spooked investors isn’t materializing the way they feared.
The company is still growing. Last fiscal year, it generated $69.7 billion in sales with 7.4% year-over-year growth. That growth is expected to continue for the fiscal year ending in August.
The valuation is attractive. The stock is priced at only 10 times this year’s expected earnings. The forward dividend yield is 4.6%. Analysts have a consensus price target of $175.41, which is 25% above the current price.
Accenture isn’t at risk from AI the way the market feared. The stock is due for a rebound once that becomes clear. At current prices, you’re getting a quality services business trading at a discount to its intrinsic value.
The Pattern: Quality Selling Into Temporary Headwinds
What these three stocks have in common is that they’re all quality businesses selling at discounts because of specific, temporary concerns that have been overpriced into the stock.
Novo Nordisk isn’t broken because of competition. It’s just facing real competitive pressure that the market has decided means the end of growth.
PepsiCo isn’t broken because of slow organic growth. It’s just facing margin pressure that the market has decided means the dividend is at risk (it’s not).
Accenture isn’t broken because of AI. It’s just facing justified concerns about technology disruption that the market has decided apply to 100% of the business (they don’t).
In each case, the market has taken a real problem and extrapolated it to an extreme conclusion. That’s created a discount you can exploit.
